Medical Retina Fellowship

在流行病学和临床应用部下的国家眼科研究所已经进行了一些医学视网膜协议。这包括针对多种常见和罕见视网膜疾病的干预性研究（I期和/或II期）和自然史研究。这些包括年龄相关性黄斑变性（AMD）、糖尿病性视网膜病变、视网膜静脉阻塞、黄斑毛细血管扩张、羟氯喹视网膜毒性、中心性浆液性脉络膜视网膜病变、遗传性视网膜疾病和Von Hippel Lindau（VHL）病。此外，筛选研究为这些试验和自然史研究提供了潜在招募的受试者。 干预性研究包括与AMD地图状萎缩的小胶质细胞抑制剂治疗相关的研究; VHL视网膜疾病的新治疗（与国家癌症研究所合作）; X连锁视网膜劈裂的基因治疗方法;以及2型黄斑毛细血管扩张症的神经保护治疗。 自然史研究包括多项与AMD相关的研究（AMD相关眼病研究（AREDS）和AREDS 2的随访; AMD患者的暗适应研究; AMD Ryan Initiative研究;地图状萎缩自然史研究），以及与羟氯喹视网膜毒性和黄斑毛细血管扩张相关的研究。生物库方案包括收集多种视网膜疾病的血液（DNA）。其他正在进行的合作研究包括HIV相关神经变性个体的视网膜发现（NINDS）和AMD的基因型-表型研究（NHGRI）。

A number of medical retinal protocols have been conducted at the National Eye Institute under the Division of Epidemiology and Clinical Applications. This includes both interventional studies (phase I and/or or II) and natural history studies for multiple common and rare retinal diseases. These include age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, macular telangiectasia, hydroxychloroquine retinal toxicity, central serous chorioretinopathy, inherited retinal diseases, and Von Hippel Lindau (VHL) disease. In addition, a screening study provides participants for potential recruitment to these trials and natural history studies. The interventional studies include those related to treatment with a microglial inhibitor for geographic atrophy in AMD; novel treatments for retinal disease in VHL (in collaboration with the National Cancer Institute); a gene therapy approach for X-linked retinoschisis; and a neuroprotective treatment for macular telangiectasia type 2. The natural history studies include multiple related to AMD (follow up of Age-Related Eye Disease Study (AREDS) and AREDS2; studies of dark adaptation in patients with AMD; the AMD Ryan Initiative Study; the geographic atrophy natural history study), as well as those related to hydroxychloroquine retinal toxicity and macular telangiectasia. The Biobank protocol includes collection of blood (DNA) for multiple retinal diseases. Other collaborative studies underway include retinal findings in individuals with HIV-related neurodegeneration (with NINDS), and genotype-phenotype studies of AMD (with NHGRI).